Skin samples from patients with systemic sclerosis (SSc) are not widely available to investigators studying pathogenesis. To derive the greatest value from these samples it is important that they are associated with clinical data, in particular the modified Rodnan skin score (MRSS), but also ideally other organ involvement The Boston University Medical Center Scleroderma Program under the leadership of Dr. Lafyatis and through NIH U01 funding has collected and is continuing to collect such well-characterized biopsies. In addition in many cases in patients with early diffuse SSc biopsies are being collected every 6 months, so that the evolution of the disease and the relationship to changes in protein staining in the skin tissues can be compared. Dr. Bhawan, Dermatopathologist and Director of the BUMC Dermatopathology Laboratory, will direct the Skin Pathology Core (Core B). The Core will process these and other biopsies provided by Core Center Investigators into 8-sample tissue blocks containing either 6 different SSc and 2 healthy control biopsies (""""""""Discovery slides""""""""), 6 temporally evolving skin changes in individual patients and 2 healthy control biopsies (""""""""Disease Progression slides""""""""), or 2 SSc and 6 other diseases including wound tissue, psoriasis, keloid and nephrogenic systemic fibrosis (Specificity slides). Murine skin will be collected from murine models of SSc: cGVHD, bleomycin, Tsk and other SSc models, as well as control mice for similar multi-tissue slide preparations. The Core will assist Investigators or stain these slides in the Core as the Investigator requests with proteins under study for new pathological processes implicated in the vasculopathy, fibrotic or immune response in SSc and murine SSc model skin. Core B will also evaluate histochemical or immunohistochemical staining intensity using quantitative (image analysis) or semi-quantitative methods. Sample staining will be correlated with MRSS and other clinical parameters, and past staining patterns in slides from the same block can also be compared. These slides will provide an unparalleled resource for discovery of pathogenic mechanisms in skin pathogenesis of SSc.
SSc is a devastating rheumatic condition often leading to death. Because the disease is uncommon, it has been difficult to organize resources and obtain adequate sample numbers to understand disease pathogenesis. This Core will provide a mechanism for obtaining skin samples from large numbers of patients for evaluation by histochemistry and immunohistochemistry.
|Urso, Katia; Alvarez, David; Cremasco, Viviana et al. (2016) IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. JCI Insight 1:|
|Ziemek, Jessica; Man, Ada; Hinchcliff, Monique et al. (2016) The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology (Oxford) 55:911-7|
|Nazari, Banafsheh; Rice, Lisa M; Stifano, Giuseppina et al. (2016) Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. Am J Pathol 186:2650-64|
|Martyanov, Viktor; Whitfield, Michael L (2016) Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data. Curr Opin Rheumatol 28:83-8|
|Mendoza, Fabian A; Piera-Velazquez, Sonsoles; Farber, John L et al. (2016) Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol 68:210-7|
|Ahluwalia, Neil; Grasberger, Paula E; Mugo, Brian M et al. (2016) Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion. Am J Respir Cell Mol Biol 54:831-42|
|Christmann, Romy B; Wooten, Alicia; Sampaio-Barros, Percival et al. (2016) miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther 18:155|
|Ramos, Paula S; Silver, Richard M; Feghali-Bostwick, Carol A (2015) Genetics of systemic sclerosis: recent advances. Curr Opin Rheumatol 27:521-9|
|Rice, Lisa M; Padilla, Cristina M; McLaughlin, Sarah R et al. (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125:2795-807|
|Roach, Katy M; Feghali-Bostwick, Carol A; Amrani, Yassine et al. (2015) Lipoxin A4 Attenuates Constitutive and TGF-Î²1-Dependent Profibrotic Activity in Human Lung Myofibroblasts. J Immunol 195:2852-60|
Showing the most recent 10 out of 33 publications